4,782 results on '"Adenoma, Islet Cell"'
Search Results
2. Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
3. Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
4. ATRX/DAXX in EUS-FNB Specimens of Pan-NETs (FORESEE)
5. Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
6. Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
7. In Vitro Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumor
8. Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms (PanNEN)
9. Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. (BANN)
10. Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
11. SSTR PET/CT for Preoperative N Stage Evaluation in GEP-NETs
12. Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
13. Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
14. Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China
15. Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours (3DPanNET)
16. Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver
17. A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
18. OPALINE : A Study Of Morbidity And Mortality At 2 Years (OPALINE)
19. Real-world Study on Adjuvant Octreotide Therapy in pNETs
20. Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
21. Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
22. Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
23. AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
24. Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
25. The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
26. A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) (REMINET)
27. Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour (NET729)
28. Neoadjuvant PRRT With Y-90-DOTATOC in pNET (NeoNet)
29. EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors
30. EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors
31. Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
32. Biomarker Study of Pancreatic Neuroendocrine Tumours
33. Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms
34. Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice. (PanNET)
35. Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors (LuX)
36. 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors (Lu-Ca-S)
37. Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
38. RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
39. Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria (CRIPNET)
40. Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib (RESUNET)
41. Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region
42. Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)
43. A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
44. Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients
45. Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors)
46. Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment (SANO)
47. A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus
48. AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
49. Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
50. Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas (CONTACT)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.